Mayo School of Continuing Medical Education
Mayo Clinic
Hyperoxaluria Center

7th International Workshop on Primary Hyperoxaluria
In Honor of Lynwood H. Smith, M.D. and David M. Wilson, M.D.

October 8–10, 2004
Mayo Clinic
Rochester, Minnesota

Call For Abstracts
Abstract Deadline: August 1, 2004
**Description**

The 7th International Workshop on Primary Hyperoxaluria will provide a forum for clinicians and scientists with expertise and interest in Primary Hyperoxaluria and oxalate related diseases to share clinical challenges, advances in diagnosis and treatment, and promising new directions for research.

**Highlights**

- Recent advances in AGT genomics and the emerging role of genetic testing for diagnosis, predicting clinical course, and guiding therapy
- Proteomics of AGT and molecular approaches to treatment
- Mechanisms of oxalate injury of cells and tissues
- Promising new therapeutics
- Insights from Primary Hyperoxaluria registry data
- Management of stone disease in patients with Primary Hyperoxaluria
- An evening honoring the work of Dr. Lynwood Smith and Dr. David Wilson

**Objectives**

- Discuss new advances in research into the molecular genetics and gene expression in Primary Hyperoxaluria
- Interpret pathophysiologic mechanisms of oxalate induced cell and tissue injury
- Recognize novel research avenues that have promise in this disease
- Describe the best current approach to diagnosis and clinical management of patients with Primary Hyperoxaluria, including the issues surrounding controversial approaches such as preemptive liver transplantation

**Date and Location**

The 7th International Workshop on Primary Hyperoxaluria will be held October 8-10, 2004. Course headquarters will be located in Geffen Auditorium, Gonda Building, Mayo Clinic, Rochester, Minnesota. Meeting facilities are easily accessible by skyway and pedestrian subway, which connect Mayo Clinic to shops, restaurants, and hotels.

**Credit**

Mayo Foundation is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to sponsor continuing medical education for physicians.

Mayo Foundation designates this educational activity for a maximum of 17.0 category 1 credits toward the AMA Physician’s Recognition Award. Each physician should claim only those credits he/she actually spent in the activity.

The American Medical Association has determined that non-US licensed physicians who participate in this CME activity are eligible for AMA PRA category 1 credit.

Other health care professionals will be provided a certificate of attendance for requesting credits in accordance with state nursing boards, specialty societies, or other professional associations.
**Intended Audience**

The 7th International Workshop on Primary Hyperoxaluria is intended for researchers, clinical laboratory personnel, clinicians, and allied health care workers involved with research in oxalate related disease or clinical care of patients with Primary Hyperoxaluria.

**Young Investigator Awards**

The 7th International Workshop on Primary Hyperoxaluria seeks to help young investigators to attend this meeting and present their work. These awards will defray part or all of the costs of travel to and accommodations at the 7th International Workshop on Primary Hyperoxaluria. Please check the box on the on-line submission form next to the Award if you wish to apply.

**Patient Program**

On October 9, a day of content will be provided for patients with Primary Hyperoxaluria and their families. This will be separate from the sessions for the medical and scientific community. Patients and their families will develop an improved understanding of Primary Hyperoxaluria, its diagnosis, conventional and investigational approaches to treatment. For further information regarding the patient program, please visit www.ohf.org.

**Registration**

To register, complete the attached registration form and return by mail or fax. The registration fee includes tuition, continental breakfasts, break refreshments, lunches, reception, and dinner. Although it is not Mayo School of Continuing Medical Education policy to limit the number of registrants for a course, conference room facilities may necessitate closing of enrollment; therefore, early registration is advised. A letter of confirmation will be sent upon receipt of payment and completed registration form. Please present the confirmation letter when checking in at the meeting registration desk.

**Cancellation Policy**

Your registration fee, less a $50 administrative fee, will be refunded when written notification is received by the Mayo School of Continuing Medical Education before September 24, 2004. No refunds will be made after September 24, 2004.

**Parking**

Parking is available in hotel, city, and Mayo patient/visitor ramps. The cost for parking is not included in the registration fee. A map indicating the location of downtown parking facilities will be mailed with the registrant confirmation letter.
Travel Arrangements

Rochester, Minnesota, is located approximately 80 miles (133 kilometers) southeast of Minneapolis/St. Paul and 40 miles (67 kilometers) west of the Mississippi River. Rochester is a friendly city that greets thousands of visitors from around the world each year. The city is served by a modern international airport with multiple flights daily from Chicago and Minneapolis via American or Northwest Airlines. Access to and from the airport is provided by taxi cab and shuttle service.

The airport is located approximately 10 driving miles from the Mayo Clinic complex. There is no shuttle service between Rochester International Airport and downtown Rochester. A taxi or van does not meet every flight. To ensure that ground transportation is waiting upon arrival, please phone Yellow Cab at 507-282-2222. Car rental is also available at the Rochester International Airport. For participants arriving via the Minneapolis/St. Paul International Airport, shuttle reservations to Rochester can be made through Rochester Direct by calling 507-280-9270.

Airfare is the sole responsibility of the individual registrant. AAA Travel has negotiated multiple airline contracts to provide attendees and their guests with the lowest available airfares. Reduced airfares are available by calling AAA Travel at 800-648-6718 or 507-289-2917, by faxing 507-289-4005, or by e-mailing jamie.lund@mn-ia.aaa.com. Please reference the Mayo Clinic Hyperoxaluria course when making travel arrangements. Reduced airfares are subject to availability. To take maximum advantage of discounted rates, it is strongly recommended that flights be booked 60 or more days prior to actual travel.

Note: Several cities in the USA are named Rochester. Be certain that your destination is Rochester, Minnesota (RST) and that your luggage is properly tagged when airline reservations are made and baggage is checked.

Lodging Accommodations

Blocks of guestrooms have been reserved with special course rates at the following downtown Rochester hotels. To ensure accommodations and the discounted rate, please make your reservations by September 10, 2004 and identify yourself as a participant of the 7th International Workshop on Primary Hyperoxaluria.

Radisson Plaza Hotel
150 South Broadway
800-333-3333 or 507-281-8000
$99 single/double

Rochester Marriott Hotel
101 First Avenue SW
877-623-7775 or 507-280-6000
$115 single/double

The hotels listed above are connected by skyway and pedestrian subway to conference facilities, downtown shops, and restaurants. You may also wish to visit the Rochester Convention and Visitors Bureau website (www.rochestercvb.org) for additional accommodation options.
Faculty Disclosure

As a provider accredited by ACCME, Mayo Foundation must ensure balance, independence, objectivity and scientific rigor in its educational activities. All faculty participating in a Mayo Foundation activity are required to disclose commitments to and/or relationships with pharmaceutical companies, biomedical device manufacturers or distributors, or others whose products or services may be considered to be related to the subject matter of the educational activity. Faculty will also disclose any off-label and/or investigational use of pharmaceuticals or instruments discussed in their presentation. Disclosure of these commitments and/or relationships will be published in course materials so those participants in the activity may formulate their own judgments regarding the presentation.

Faculty

Mayo Clinic Faculty

Dawn S. Milliner, M.D.
Course Director
Mayo Clinic Hyperoxaluria Center

Timothy S. Larson, M.D.
Division of Nephrology and Hypertension

John C. Lieske, M.D.
Mayo Clinic Hyperoxaluria Center

Carla G. Monico, M.D.
Mayo Clinic Hyperoxaluria Center

David O. Toft, Ph.D.
Department of Biochemistry and Molecular Biology

Terri J. Vrtiska, M.D.
Department of Radiology
Mayo Clinic Hyperoxaluria Center

Distinguished Guest Faculty

Antonio Amoroso, Ph.D.
Universita degli studi di Trieste
Trieste, Italy

Dean Assimos, M.D.
Wake Forest University School of Medicine
Winston-Salem, North Carolina

Jayanta Ray-Chowdhury, M.D.
Albert Einstein College of Medicine
Bronx, New York

Pierre Cochot, M.D.
Hospital E Herriot
Lyon, France

Fred Coe, M.D.
University of Chicago
Chicago, Illinois

Marion Coulter-Mackie, Ph.D.
British Columbia’s Children’s Hospital
Vancouver, Canada

Scott Cramer, Ph.D.
Wake Forest University School of Medicine
Winston-Salem, North Carolina

Christopher J. Danpure, Ph.D.
University College London
London, United Kingdom

Andrew Evan, M.D.
Indiana University
Indianoplis, Indiana

Yaacov Frishberg, M.D.
Shaare Zedek Medical Center
Jerusalem, Israel

Larry Greenbaum, M.D.
Medical College of Wisconsin
Milwaukee, Wisconsin

Jaap Groothoff, M.D.
Emma Children’s Hospital/AMC
Amsterdam, The Netherlands

Marguerite Hatch, Ph.D.
University of Florida
Gainesville, Florida

Albrecht Hesse, M.D.
Experimentelle Urologie
Klinik und Poliklinik fur Urologie
Bonn, Germany

Ross Holmes, Ph.D.
Wake Forest University School of Medicine
Winston-Salem, North Carolina

Bernd Hoppe, M.D.
University Children’s Hospital
Cologne, Germany
<table>
<thead>
<tr>
<th>Name</th>
<th>Institution</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>Arata Ichiyama, M.D., Ph.D.</td>
<td>Hamamatsu University School of Medicine</td>
<td>Hamamatsu, Japan</td>
</tr>
<tr>
<td>Neville Jamieson, M.D.</td>
<td>Addenbrooke’s Hospital</td>
<td>Cambridge, United Kingdom</td>
</tr>
<tr>
<td>Julie Jonassen, Ph.D.</td>
<td>University of Massachusetts</td>
<td>Worcester, Massachusetts</td>
</tr>
<tr>
<td>Markus J. Kemper, M.D.</td>
<td>University Children’s Hospital</td>
<td>Hamburg, Germany</td>
</tr>
<tr>
<td>Saeed Khan, Ph.D.</td>
<td>University of Florida College of Medicine</td>
<td>Gainesville, Florida</td>
</tr>
<tr>
<td>Hari Koul, M.D.</td>
<td>University of Colorado School of Medicine</td>
<td>Denver, Colorado</td>
</tr>
<tr>
<td>Craig Langman, M.D.</td>
<td>Children’s Memorial Hospital</td>
<td>Chicago, Illinois</td>
</tr>
<tr>
<td>Kay Latta, M.D.</td>
<td>Kinderklinik der MHH</td>
<td>Hannover, Germany</td>
</tr>
<tr>
<td>Norbert Laube, Ph.D.</td>
<td>Experimentelle Urologie</td>
<td>Bonn, Germany</td>
</tr>
<tr>
<td>Ernst Leumann, M.D.</td>
<td>University Children’s Hospital</td>
<td>Zurich, Switzerland</td>
</tr>
<tr>
<td>Martino Marangella, M.D.</td>
<td>Ospedale Mauriziano</td>
<td>Torino, Italy</td>
</tr>
<tr>
<td>Rana Muzzaffar, M.D.</td>
<td>Civil Hospital and Dow Medical College</td>
<td>Karachi, Pakistan</td>
</tr>
<tr>
<td>Gillian Rumsby, Ph.D.</td>
<td>University College London Hospitals</td>
<td>London, United Kingdom</td>
</tr>
<tr>
<td>Tatsuya Takayama, M.D., Ph.D.</td>
<td>Hamamatsu University School of Medicine</td>
<td>Hamamatsu, Japan</td>
</tr>
<tr>
<td>Jorge E. Toblli, M.D., Ph.D.</td>
<td>Hospital Alemán</td>
<td>Buenos Aires, Argentina</td>
</tr>
<tr>
<td>David Valle, M.D.</td>
<td>Johns Hopkins University</td>
<td>Baltimore, Maryland</td>
</tr>
<tr>
<td>Carl Verkoelen, M.D.</td>
<td>Erasmus University</td>
<td>Rotterdam, The Netherlands</td>
</tr>
<tr>
<td>Paul Walton, Ph.D.</td>
<td>University of Western Ontario</td>
<td>London, Ontario, Canada</td>
</tr>
<tr>
<td>Elaine Worcester, M.D.</td>
<td>University of Chicago</td>
<td>Chicago, Illinois</td>
</tr>
</tbody>
</table>

**Posters**

**Overview:** As part of the 7th International Workshop on Primary Hyperoxaluria, a poster session will be held for presentation of original research in the field of Primary Hyperoxaluria and oxalate related disease. Posters of particular interest will be selected for brief oral presentation and discussion. Any projects relevant to the field of Primary Hyperoxaluria are welcome. Posters will be chosen from all abstracts received by the **August 1, 2004** submission deadline.

**Abstract Eligibility:** In order to maximize participation and sharing of ideas, relevant and interesting abstracts that either have or have not been presented at other meetings will be considered.

**Deadline:** Abstract submission deadline is **August 1, 2004**.

**Instructions for on-line submission of abstracts are attached.**

**Notification of Results:** All primary authors will be notified by **September 1, 2004** if their submission has been selected for the poster session and/or for presentation at the poster discussion session. Details regarding poster set-up will follow.

**Printing of Abstracts:** Abstracts chosen for presentation will be printed in the course syllabus.

**Inquiries:** For further information, contact Monica Poncelet at poncelet.monica@mayo.edu.
**Program Schedule**

**Friday, October 8, 2004**

**SESSION 1**  **IS GENOTYPE IMPORTANT FOR DIAGNOSIS OR PROGNOSIS OF PATIENTS WITH PRIMARY HYPOXALURIA?**  
**Session Chair – Ernst Leumann, M.D.**

This session will highlight recent advances in AGT genomics and the emerging role of genetic testing for predicting clinical course and guiding therapy. The session will be framed via a keynote address to discuss the challenges in establishing genotype/phenotype correlations in autosomal recessive disorders.

2:00 p.m.  **Keynote Address: Genotype/Phenotype Correlations in Autosomal Recessive Diseases**  
David Valle, M.D.

2:40 p.m.  **Genotype/Phenotype Correlations in Populations with Primary Hyperoxaluria**  
Southern Europe – Antonio Amoroso, Ph.D.  
Middle East – Yaacov Frishberg, M.D.  
Japan - Arata Ichiyama, M.D., Ph.D.  
Tatsuya Takayama, M.D., Ph.D.

Are there Ethnic Differences in Primary Hyperoxaluria Genotype?  
Marion Coulter-Mackie, Ph.D.

Genotype as a Tool to Determine Pyridoxine Responsiveness  
Carla G. Monico, M.D.

4:40 p.m.  **Overview: The Role of Genotyping in Diagnosis of Primary Hyperoxaluria**  
Gillian Rumsby, Ph.D.

Panel Discussion Regarding the Role of Genotype in Diagnosis  
Scott Cramer, Ph.D.  
Jaap Groothoff, M.D.  
Martino Marangella, M.D.

5:40 p.m.  Adjournment

**Saturday, October 9, 2004**

**SESSION 2**  **INSIGHTS FROM REGISTRY DATA**  
**Session Chair – Larry Greenbaum, M.D.**

This session will provide an update on insights gathered from both European and American registries. The European registry tracks outcomes after liver transplantation for Primary Hyperoxaluria and will serve as the basis of a panel discussion regarding a controversial treatment approach using preemptive liver transplantation prior to the development of renal failure.

8:00 a.m.  **Primary Hyperoxaluria Registry Reports**

Report from Germany and US Survey  
Bernd Hoppe, M.D.

Report from the International Registry  
Dawn S. Milliner, M.D., John C. Lieske, M.D.

Report from the European Transplant Registry  
Neville Jamieson, M.D.

9:00 a.m.  **Panel Discussion: Is There a Role for Preemptive Liver**
Transplantation in Primary Hyperoxaluria?

Discussion Chair – Markus J. Kemper, M.D.
Discussants – Yaacov Frishberg, M.D.
Craig Langman, M.D.
Pierre Cochat, M.D.

10:00 a.m. Refreshment Break

SESSION 3 Oxalate Injury
Session Chair – Fred Coe, M.D.

This session will highlight new insights into the mechanisms by which oxalate damages renal cells and tissues, with the goal of identifying new therapeutic targets.

10:15 a.m. Overview: Mechanisms of Oxalate Injury
Carl Verkoelen, M.D.

Oxalate Toxicity to Cells
Julie Jonassen, Ph.D.

Diverse Responses of Renal Cells to Oxalate
John C. Lieske, M.D.

Prevention of Tissue Injury with ACE Inhibition
Jorge Toblli, M.D., Ph.D.

Antioxidants for Renal Protection in Hyperoxaluria
Saeed Khan, Ph.D.

A New Animal Model of Hyperoxaluria
Elaine Worcester, M.D.

12:15 p.m. Luncheon and Poster Viewing

1:15 p.m. Poster Discussion
Chair – Marguerite Hatch, Ph.D.

SESSION 4 Molecular Approaches to Treatment
Session Chair – Craig Langman, M.D.

Protein folding and misfolding, including the role of chaperones, is an important and emerging area of study in human diseases, including Primary Hyperoxaluria. This session will underscore new information in this area and relate it back to Primary Hyperoxaluria pathogenesis, including therapeutic implications.

2:00 p.m. Keynote Address: Molecular Chaperones
David O. Toft, Ph.D

2:40 p.m. Overview: Advances in Molecular Biology of Primary Hyperoxaluria – New Directions for Treatment
Christopher J. Danpure, Ph.D.

Protein Structure and Import into the Peroxisomal Matrix
Paul Walton, Ph.D.

Cell Transfection to Deliver AGT to Hepatocytes
Hari Koul, M.D.

Hepatic Cellular Therapies: Are They Feasible?
Jayanta Roy-Chowdhury, M.D.

6:30 p.m. Dinner
7:00 p.m. **Evening Session**

**Tribute to Dr. Lynwood Smith and Dr. David Wilson**

Fred Coe, M.D., Keynote Speaker
Christopher P. Danpure, Ph.D.
Dawn S. Milliner, M.D.
Timothy S. Larson, M.D.

---

**Sunday, October 10, 2004**

**SESSION 5  ADVANCES IN MANAGEMENT OF DISEASE**

**Session Chair – Kay Latta, M.D.**

This session will highlight additional therapeutic options for Primary Hyperoxaluria not previously discussed, including use of probiotics and other methods to hasten oxalate elimination via alternative pathways.

8:00 a.m. **Overview: Promise and Progress in Disease Management**

Pierre Cochat, M.D.

Opportunistic Use of Alternative Metabolic Pathways
Ross Holmes, Ph.D.

Role of Oxalobacter in GI Disposition of Oxalate
Rana Muzzaffar, M.D.

Oxalobacter and Other Bacterial Therapies
Bernd Hoppe, M.D.

10:00 a.m. **Refreshment Break**

**SESSION 6  UROLITHIASIS IN PRIMARY HYPEROXALURIA**

**Session Chair – Martino Marangella, M.D.**

Prior to development of renal failure, urolithiasis dominates the clinical management of Primary Hyperoxaluria patients. The final session will emphasize stone formation in Primary Hyperoxaluria, including new tools to assist in management.

10:15 a.m. **Overview: Stone Management in Patients with Marked Hyperoxaluria – Pitfalls to be Avoided**

Dean Assimos, M.D.

Bonn Risk Index
Albrecht Hesse, M.D.

Norbert Laube, M.D., Co-Author

Quantitation of Stone Burden
Terri J. Vrtiska, M.D.

Insights from Pathology of Stone Formation
Andrew Evan, M.D.

**SUMMARY SESSION**

12:15 p.m. **Roundtable Discussion: New Insights from Each Session**

Session Chairs

1:00 p.m. **Adjournment**
ABSTRACT SUBMISSION FORMAT

Guidelines for submission of abstracts are at: www.ohf.org, in pdf format.

1. Please complete the abstract form, print it, and return to us via FAX or conventional mail at:

   Fax: 507-266-7891

   Dawn S. Milliner, M.D.
   c/o Monica Poncelet
   Mayo Clinic
   200 First Street SW
   Rochester, MN 55905

2. The abstract, once accepted, may be published using direct photo reproduction and thus, will appear exactly as typed. Use only the New Roman font size of 12 pitch (12 characters to the inch).

3. Abstracts must be submitted by August 1. Confirmation of acceptance will be communicated to the presenting author by September 1, 2004.

4. The exact schedule of presentation will be communicated to the Presenting Author by or before September 1, 2004.

5. Mailing address – Any communications regarding the acceptance will be given to the Presenting Author at the indicated address.

ABSTRACT FORM

Abstract submission deadline: August 1, 2004
Registration Form

7th International Workshop on Primary Hyperoxaluria
October 8-10, 2004 Mayo Clinic • Rochester, Minnesota, USA

Mail or FAX this completed registration form to:
Mayo School of Continuing Medical Education
200 First Street SW
Rochester, MN 55905

Telephone: 800-323-2688 or 507-284-2509
FAX: 507-284-0532
E-mail: cme@mayo.edu
Website: www.mayo.edu/cme

(Please print or type all information. You may duplicate this form for multiple registrations.)

Name_________________________ First Name ______________________ Middle Name or Initial _______ Last Name ______________________

Degree □ MD □ PhD □ RN □ Other_________________________

Institution ______________________

Medical Specialty ______________________

E-mail Address ______________________

Which is your preferred mailing address: □ Work/Business □ Home

Address _____________________________

City __________________ State/PV ______ ZIP/Postal Code ______ Country__________

Home Telephone (_____ ) ____________ Business Telephone (_____ )_________

Int’l Telephone (Country code) ________(City code) ______(Phone) ___________ 

FAX ____________________________

□ Please check if you are applying for a Young Investigator Award to defray travel costs. Applicants should be fewer than 5 years from obtaining their degree.

□ Please check if you have any special assistance needs or dietary restrictions. Please indicate your needs here: ____________________________

Reception, Friday Evening, October 8, 2004

□ Yes, I plan to attend. (Complimentary)
□ No, I do not plan to attend.

□ Yes, I plan to attend with guest(s). Number of tickets _____ @ $35 each $ ___________

Dinner, Saturday Evening, October 9, 2004

□ Yes, I plan to attend. (Complimentary)
□ No, I do not plan to attend.

□ Yes, I plan to attend with guest(s). Number of tickets _____ @ $45 each $ ___________

PAYMENT

Registration Fee: $300 ___________
Guest Reception Ticket: (# ____ @ $35) $ ___________
Guest Dinner Ticket: (# ____ @ $45) $ ___________
Total Payment Enclosed: $ ___________

□ Check (payable to Mayo Foundation)
□ Credit Card: □ Visa □ MasterCard □ Discover

Cardholder’s Name ____________________________

Card Number ____________________________ Expiration Date ____________________________
7th International

Workshop on Primary Hyperoxaluria

October 8–10, 2004

Mayo Clinic
Rochester, Minnesota